Results 291 to 300 of about 494,667 (340)

Effects of tibolone on lipoprotein(a) and HDL subfractions

Maturitas, 1994
To determine the effects of tibolone, a synthetic steroid used to alleviate climacteric symptoms and prevent osteoporosis, on lipoprotein metabolism, with particular reference to lipoprotein(a) levels and HDL subfraction profiles.Thirty nine postmenopausal women were treated with tibolone (Livial) 2.5 mg/day for 6 months and fasting serum lipoprotein ...
E, Farish, J F, Barnes, H A, Rolton, K, Spowart, C D, Fletcher, D M, Hart   +5 more
openaire   +2 more sources

HDL cholesterol and ASCVD risk stratification: A debate.

Atherosclerosis, 2019
This debate is designed to review the usefulness of the cholesterol mass within high-density lipoproteins (HDL-C) to predict the risk of atherosclerotic cardiovascular disease (ASCVD).
P. Barter, J. Genest
semanticscholar   +1 more source

Interaction of apoHDL with HDL and with other lipoproteins

Atherosclerosis, 1970
Abstract Ultracentrifugation at a density of 1.21 of mixtures of apoHDL and HDL in which one component was labeled with 125 I showed that interchange of labeled protein took place. Since no evidence of intermediates was obtained it seems more probable that these results are explained by interchange of the relatively small protein subunits (mol.wt ...
H S, Sodhi, R G, Gould
openaire   +2 more sources

Plasma lipoprotein abnormalities in a case of primary high‐density‐lipoprotein (HDL) deficiency

Clinical Genetics, 1975
A 53‐year‐old patient with primary HDL‐deficiency is reported. About 2% of the normal concentration of alpha1 HDL was present in his plasma. The alphal‐high‐density‐lipopro‐teins separated into two fast‐moving components in polyacrylamide gel electrophoresis.
G, Utermann, H J, Menzel, W, Schoenborn
openaire   +2 more sources

High Density Lipoprotein (HDL) Modulation Targets.

Drugs of the future
Given the strong genetic determinants of favorable HDL-C levels, the ability to procure the cardiovascular disease and longevity benefits associated with this mediator of the reverse cholesterol transport pathway through pharmaceutical intervention is challenging.
Shaymaa S, Mousa, Robert C, Block, Shaker A, Mousa   +2 more
openaire   +1 more source

High-Density Lipoprotein (HDL)

2012
Robert L. Sainburg, Andrew L. Clark, George E. Billman, Zachary J. Schlader, Toby Mündel, Kevin Milne, Earl G. Noble, Felipe Querol, Sofia Pérez-Alenda, José A. Aznar, Stavros Apostolakis, Gregory Y. H. Lip, W. Todd Cade, Kevin E. Yarasheski, Linda S. Pescatello, R. H. Fagard, Fabio Manfredini, Roberto Manfredini, Nancy J. Rehrer, Lawrence E. Armstrong, Gemma A. McLeod, Louise Østergaard, Max Gassmann, Luigi Varesio, Michele Samaja, Michael Vogt, Fabio Breil, Hans Hoppeler   +27 more
openaire   +2 more sources

Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL.

Atherosclerosis, 2015
I. Sutter, S. Velagapudi, A. Othman, M. Riwanto, Jasmin Manz, L. Rohrer, K. Rentsch, T. Hornemann, U. Landmesser, A. von Eckardstein   +9 more
semanticscholar   +1 more source

Athero-protective Effects of High Density Lipoproteins (HDL): An ODE Model of the Early Stages of Atherosclerosis

Bulletin of Mathematical Biology, 2014
A. Cohen, M. Myerscough, R. S. Thompson
semanticscholar   +1 more source

High-density lipoproteins, reverse cholesterol transport and atherogenesis

Nature Reviews Cardiology, 2021
H. Pownall, C. Rosales, B. Gillard, A. Gotto   +3 more
semanticscholar   +1 more source

Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations

Nature Reviews Nephrology, 2021
H. Noels, M. Lehrke, R. Vanholder, J. Jankowski   +3 more
semanticscholar   +1 more source